Wilmington, Massachusetts-based Charles River Laboratories International, Inc. (CRL) provides drug discovery, non-clinical ...

Charles River Laboratories International (NYSE:CRL – Get Free Report) was downgraded by equities research analysts at William ...

Analysts have recently evaluated Charles River and provided 12-month price targets. The average target is $214.5, accompanied by a high estimate of $250.00 and a low estimate of $185.00. A 2.72% drop ...

Fintel reports that on January 22, 2025, William Blair downgraded their outlook for Charles River Laboratories International ...

William Blair downgraded Charles River Laboratories to market perform citing concerns over a decline in early-stage R&D funding from large pharmas. Read more here.

William Blair downgraded Charles River (CRL) to Market Perform from Outperform.Invest with Confidence: Follow TipRanks' Top Wall Street ...

A February meeting could bring about the end of the trade in macaque monkeys commonly used in medical research.

The stock's rise snapped a four-day losing streak.

Riverwater Partners, an investment management company, released its “Sustainable Value Strategy” Q4 2024 investor letter. A ...

Charles River Laboratories International, Inc. today announced the launch of Apollotm for CRADL®, a secure cloud-based platform that enhances leading vivarium rental services through a digital ...

Upslope Capital Management, an investment management firm, released its fourth-quarter 2024 investor letter. A copy of the ...